Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A method of treating uveal melanoma said method comprising administrating to a mammalin need of such a treatment, a therapeutically-affective does not methanesuffonate sait of 4-(4-methy) piperazin-1-yimethy)-N-(4-methyl-3-(4-pyridin-3-yi) pyrimidin-2-yiamino) phenyl-benzamide ex-pharmaceusically-acceptable-sait-thereof in a therapeutically reforce to compromise call death in uveal melanoma.

Claim 2 (previously presented): The method according to claim 1 wherein the uveal melanoma is a metastasizing uveal melanoma.

Claims 3-4 (canceled)

Claim 5 (currently amended): The method according to claim [[4]] 1 wherein the methanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3vljoyrimidin-2-ylaminolphenyll-benzamide is in the beta crystal form.

Claim 6 (currently amended): The method according to claim 1 wherein the methanesulfortate sait of 44-methylipicerazin-1-y/methyly-N-(4-methyl-3-(4-pyridin-3-y/l)pyrimidin-2ylamino)phenyll-benzamide is administered at a daily dose corresponding to 100 mg to 1000 mg of free base.

Claim 7 (currently amended): The method according to claim 6 wherein the methanesulfonate salt of 4 (4-methylipierazin-1-yimethyl)-N-(4-methyl-3-(4-pyridin-3-yl)pyrimidin-2vlaminoiphenyll-benzamide is administered once delly for a period exceeding 3 months.

Claims 8-10 (canceled)